TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01745510

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Docosahexaenoic acid (DHA)
Description: Docosahexaenoic acid from algae source
Study: NCT02726620

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Central neuraxial anesthesia
Description: Regional anesthesia effectuated through the placement of local anesthetics around the nerves of the central nervous system, e.g. spinal anesthesia and epidural anesthesia.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Central neuraxial anesthesia
Description: Regional anesthesia effectuated through the placement of local anesthetics around the nerves of the central nervous system, e.g. spinal anesthesia and epidural anesthesia.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-cardiac surgery
Description: Any surgical intervention that is not aimed at surgical correction of the heart
Study: NCT01745510

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo was designed to mimic the color and consistence of the oil that contains DHA
Study: NCT00169832

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rosiglitazone or placebo
Description: Rosiglitazone 4 to 8 mg/day or placebo, for 12 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosiglitazone or placebo
Description: Rosiglitazone 4 to 8 mg/day or placebo, for 12 months
Study: NCT00581555

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etanercept
Description: Etanercept 50 mg QW initiated during taper of ciclosporin

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Randomized to placebo during taper of ciclosporin
Study: NCT03831126

Intervention type: DRUG
Intervention: Betamethason Sodium Phosphate
Description: First measurement: 12-36 hours after betamethasone treatment Second measurement: within five days after betamethasone treatment and two weeks Third measurement (neonatal measurement): 1-8 weeks after birh
Study: NCT00504400

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravitreal injection ranibizumab
Description: Monthly intravitreal injection of of 0.5mg ranibizumab in one eye over one year
Study: NCT03274817

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram Pill
Description: Subjects randomized to group A will receive Lexapro (escitalopram), in an initial, baseline dosage of 5 mg daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Venlafaxine Pill
Description: Subjects randomized to group B will receive Effexor XR (venlafaxine extended release capsules), in an initial baseline dosage of 37.5 mg daily.
Study: NCT00509691

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cytomegalovirus pp65-specific cytotoxic T lymphocytes

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: polymerase chain reaction
Study: NCT01819636

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: sparkling highly mineral bicarbonated sodium water
Description: 1,25 liter a day at the mealtimes
Study: NCT00509691

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: diagnostic laboratory biomarker analysis
Study: NCT03274817

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Subjects randomized to group C will receive placebo tablets, which will be matched to the Lexapro and the Effexor XR as far as possible, and will also be administered on a once daily schedule at baseline.
Study: NCT02759458

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smith & Nephew Healicoil Anchor

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Smith & Nephew Twinfix Anchor
Study: NCT01351636

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arotinolol Hydrochloride
Description: Antihypertensive medications plus arotinolol hydrochloride, dosage of arotinolol hydrochloride from 2.5mg bid, 2 days later increased to 5mg bid or 10mg bid, for 18 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Non arotinolol group
Description: Antihypertensive medications without arotinolol for 18 months
Study: NCT02642900

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Photodynamic Therapy
Description: evaluate the effectiveness of photodynamic therapy (PDT) in the treatment of denture stomatitis in complete denture wearers.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nystatin 100.000 units
Description: Control group treated with nystatin
Study: NCT02726620

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non-cardiac surgery
Description: Any surgical intervention that is not aimed at surgical correction of the heart

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Anesthetic drug used to maintain general anesthesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Anesthetic drug used to maintain general anesthesia

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: Anesthetic drug used to maintain general anesthesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: Anesthetic drug used to maintain general anesthesia

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desflurane
Description: Anesthetic drug used to maintain general anesthesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desflurane
Description: Anesthetic drug used to maintain general anesthesia

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoflurane
Description: Anesthetic drug used to maintain general anesthesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isoflurane
Description: Anesthetic drug used to maintain general anesthesia

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ephedrine
Description: Cardiovascular drug used to treat intraoperative hypotension

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ephedrine
Description: Cardiovascular drug used to treat intraoperative hypotension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenylephrine
Description: Cardiovascular drug used to treat intraoperative hypotension

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenylephrine
Description: Cardiovascular drug used to treat intraoperative hypotension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norepinephrine
Description: Cardiovascular drug used to treat intraoperative hypotension

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norepinephrine
Description: Cardiovascular drug used to treat intraoperative hypotension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epinephrine
Description: Cardiovascular drug used to treat intraoperative hypotension

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epinephrine
Description: Cardiovascular drug used to treat intraoperative hypotension
Study: NCT03998072

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Five session cognitive analytic therapy (CAT) consultancy
Description: Five session consultancy with patients and care coordinators using cognitive analytic therapy
Study: NCT03768375

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: conventional chemotherapy(FORFIRINOX) combined with target agents
Description: Drug: FORFIRINOX Conventional chemotherapy:gemcitabine and oxaliplatin Drug: Cetuximab Drug: Trastuzumab Drug: Gefitinib Drug: Lapatinib Drug: Everolimus Drug: Sorafenib Drug: Crizotinib

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: conventional chemotherapy(FORFIRINOX)
Description: conventional chemotherapy(FORFIRINOX)
Study: NCT00712504

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sunitinib
Description: 25, 37.5 and 50 mg/day, oral, administered on an outpatient basis in two different dosing regimens: schedule 2/1 (2 weeks on, 1 week off) and schedule 4/2 (4 weeks on, 2 weeks off)
Study: NCT02726620

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dobutamine
Description: Cardiovascular drug used to treat intraoperative hypotension
Study: NCT00712504

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: 60, 75, and 100 mg/m2 docetaxel administered every 21 days as a 1-hr IV infusion
Study: NCT00295802

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Integrated Imaging High Intensity Focused Ultrasound
Study: NCT03118466

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: A Drug that interfere with the action of topoisomerase enzymes (topoisomerase I and II). Topoisomerase enzymes control the manipulation of the structure of DNA necessary for replication.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA.
Study: NCT00509691

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: flow cytometry

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunologic technique
Study: NCT00409266

Intervention type: DEVICE
Group type: OTHER
Intervention: Computer assisted navigation
Study: NCT02905955

Intervention type: DEVICE
Group type: OTHER
Intervention: Prevena, KCI, Acelity, NPWT
Description: All patients will receive a Prevena NPWT (if inclusion criteria are met)
Study: NCT02078843

Intervention type: DRUG
Group type: OTHER
Intervention: Gallium-68-DOTATATE PET/CT (index test)
Description: Somatostatin-based imaging tracer

Intervention type: DRUG
Group type: OTHER
Intervention: Indium-111-Octreoscan (standard test)
Description: Somatostatin-based imaging tracer
Study: NCT02622776

Intervention type: OTHER
Group type: OTHER
Intervention: Vaginal DNA Collection
Description: Vaginal self-swab, 6hr tampon collection and response to an acceptability questionnaire
Study: NCT03870217

Intervention type: BEHAVIORAL
Intervention: Site selection
Description: Turning off electrodes on the electrode array based on imaging and psychophysical measures
Study: NCT01171807

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dex 21-P
Description: At each procedure 50 ml of patient whole blood was washed with saline solution and centrifugated. The isolated erythrocytes were suspended into 2 hypotonic solutions to make their membrane permeable and incubated with Dex 21-P sodium salt up to obtain a final concentration of 10 mM. The drug loaded erythrocytes were immediately re-infused by using a suitable filter.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients assigned to placebo arm performed the same procedure as the patients assigned to the DEX 21-P group without loading in the Red Blood Cells the Dex 21-P
Study: NCT04083677

Intervention type: DEVICE
Intervention: SONAR
Description: A curved low- frequency (2-5 MHZ) probe and (simens ACUSON x 300) ultrasound system will be used. All patient will be first scanned in the supine position, followed by the right lateral decubitus (RLD) position. The gastric antrum was identified in a sagittal scanning plane in the epigastrium immediately inferior to xiphoid and superior to umbilicus. The liver anteriorly and the aorta, inferior vena cava and pancreas posteriorly were used as anatomical reference points.

Intervention type: DEVICE
Intervention: SONAR
Description: A curved low- frequency (2-5 MHZ) probe and (simens ACUSON x 300) ultrasound system will be used. All patient will be first scanned in the supine position, followed by the right lateral decubitus (RLD) position. The gastric antrum was identified in a sagittal scanning plane in the epigastrium immediately inferior to xiphoid and superior to umbilicus. The liver anteriorly and the aorta, inferior vena cava and pancreas posteriorly were used as anatomical reference points.
Study: NCT05016362

Intervention type: PROCEDURE
Intervention: medial fat preservation upper blepharoplasty
Description: medial fat preservation upper blepharoplasty increasing volumetric upper eyelid skin fold

Intervention type: PROCEDURE
Intervention: medial fat preservation upper blepharoplasty
Description: medial fat preservation upper blepharoplasty increasing volumetric upper eyelid skin fold
Study: NCT04394208

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Silymarin
Description: Silymarin Oral at a dose of 420 mg/day in 3 divided doses.
Study: NCT03118466

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: It may act by inhibiting the growth of new blood vessels (angiogenesis) in tumors, enhancing the status of the immune system, or decreasing cytokine and growth factor production

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone
Description: It interfere with cell reproduction
Study: NCT05054868

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone
Description: Subjects randomized to the control group will receive oxycodone for postop pain management (standard of care).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone
Description: Subjects randomized to the control group will receive oxycodone for postop pain management (standard of care).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac
Description: Subjects randomized to the treatment group will receive oxycodone and ketorolac for postop pain management.
Study: NCT04550949

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QL1206
Description: The active ingredient of QL1206 is a recombinant human anti-RANKL monoclonal antibody ,subcutaneous injection of 120 mg (1.7ml)every 4 weeks for a maximum of 13 consecutive doses throughout the trial.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Xgeva
Description: The active ingredient of Xgeva® is denosumab,subcutaneous injection of 120 mg (1.7ml)every 4 weeks for a maximum of 13 consecutive doses throughout the trial.
Study: NCT05431868

Intervention type: OTHER
Intervention: AT LISA tri 839MP (Carl Zeiss Meditec AG)
Description: This prospective cohort study collected data of patients who underwent bilateral or unilateral cataract surgery with the AT LISA tri 839MP implantation.

Intervention type: OTHER
Intervention: AT LISA tri 839MP (Carl Zeiss Meditec AG)
Description: This prospective cohort study collected data of patients who underwent bilateral or unilateral cataract surgery with the AT LISA tri 839MP implantation.

Intervention type: OTHER
Intervention: AT LISA tri 839MP (Carl Zeiss Meditec AG)
Description: This prospective cohort study collected data of patients who underwent bilateral or unilateral cataract surgery with the AT LISA tri 839MP implantation.
Study: NCT02398188

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LIPO-202

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01952249

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Demcizumab
Description: administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Demcizumab
Description: administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taxol
Description: administered intravenously
Study: NCT04394208

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo comparator
Study: NCT02138955

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomeal curcumin
Study: NCT00295802

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endocare CRYOcare Cryosurgical and Galil Medical CRYO-HIT Systems (cryotherapy)
Description: Cryotherapy
Study: NCT00703937

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferric Carboxymaltose (FCM)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Medical Care (SMC) for the treatment of IDA
Study: NCT03789448

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early Access to ART for All
Description: All HIV-positive individuals will be initiated on Swaziland's recommended first-line ART regimen, unless contraindicated when recommended alternate regimens will be used per national guidelines
Study: NCT04401501

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual Therapy and Exercises
Description: Combination of physiotherapy (manual therapy) techniques and exercises for cervicogenic headache

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Exercises for cervicogenic headache
Study: NCT01952249

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taxol
Description: administered intravenously
Study: NCT03913000

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ID-085
Description: Hard capsules for oral administration formulated at a strength of 200 mg
Study: NCT00747175

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1656
Description: Dose titration to 3 (alt 4) increasing dose-steps with oral suspension, 8 days treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1656
Description: Dose titration of oral suspension to a tolerable dose, 1 month treatment
Study: NCT03997370

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV
Study: NCT00370305

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rosiglitazone
Description: 89 mg BID for 8 weeks, orally
Study: NCT04513652

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG-920
Description: AG-920 Sterile Topical Ophthalmic Solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Topical Ophthalmic Solution
Study: NCT04842929

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial magnetic stimulation
Description: The coil will be positioned in the prefrontal dorsolateral cortex, with intermintent TBS (TBSi) mode on the left and continuous TBS (TBSc) on the right. 1800 pulses will be used on each side, totaling 10 minutes of total duration. There will be 20 consecutive sessions, one per day, except on weekends and holidays, totaling around 4 weeks. A day of stimulation with the same technique will be done in the 6th week, 8th week and 12th week.
Study: NCT02980315

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CAR-T cells
Description: the patients treat with CAR-T cells
Study: NCT04049461

Intervention type: DIAGNOSTIC_TEST
Intervention: Bone alkaline phosphatase
Description: Hematologic indicators reflecting ossification.

Intervention type: DIAGNOSTIC_TEST
Intervention: Bone alkaline phosphatase
Description: Hematologic indicators reflecting ossification.

Intervention type: RADIATION
Intervention: Abdominal CT scan
Description: Observe whether HOAI occurs.

Intervention type: RADIATION
Intervention: Abdominal CT scan
Description: Observe whether HOAI occurs.
Study: NCT04611815

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total knee arthroplasty
Description: Participant will undergo robotic-assisted or conventional total knee arthroplasty
Study: NCT04842929

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial magnetic stimulation
Description: The coil will be positioned in the prefrontal dorsolateral cortex, with intermintent TBS (TBSi) mode on the left and continuous TBS (TBSc) on the right. 1800 pulses will be used on each side, totaling 10 minutes of total duration. There will be 20 consecutive sessions, one per day, except on weekends and holidays, totaling around 4 weeks. A day of stimulation with the same technique will be done in the 6th week, 8th week and 12th week.
Study: NCT04611815

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total knee arthroplasty
Description: Participant will undergo robotic-assisted or conventional total knee arthroplasty

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Computer tomography scan
Description: CT scans of the affected knee joint before and after the surgical procedure

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Computer tomography scan
Description: CT scans of the affected knee joint before and after the surgical procedure

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: biomechanical assesment
Description: Participants will be asked to perform biomechanical assesment before and following surgery at baseline, 6-8 weeks and 6-months postoperatively

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: biomechanical assesment
Description: Participants will be asked to perform biomechanical assesment before and following surgery at baseline, 6-8 weeks and 6-months postoperatively
Study: NCT02324153

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramelteon
Description: 1 pre-operative and 2 nightly postoperative doses of Ramelteon/placebo will be administered

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Microcrystalline Cellulose
Description: Placebo Comparator

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Microcrystalline Cellulose
Description: Placebo Comparator

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Riboflavin 100 mg
Description: Riboflavin will be added to both placebo and active intervention capsules in order to track adherence to dose while taken as an outpatient (i.e. only the first preoperative dose)
Study: NCT03250234

Intervention type: OTHER
Group type: OTHER
Intervention: Adequate Carbohydrate
Description: During the 3-hr recovery period after glycogen depletion participants will consume a carbohydrate (1 g/kg/hr) beverage For the day participants will consume a diet of 6.0 g/kg/d carbohydrate following glycogen depletion
Study: NCT02324153

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riboflavin 100 mg
Description: Riboflavin will be added to both placebo and active intervention capsules in order to track adherence to dose while taken as an outpatient (i.e. only the first preoperative dose)